Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

Open access
Landovitz, Raphael J, Li, Sue, Eron, Joseph J, Grinsztejn, Beatriz, Dawood, Halima, Liu, Albert Y, Magnus, Manya, Hosseinipour, Mina C, Panchia, Ravindre, Cottle, Leslie, Chau, Gordon, Richardson, Paul, Marzinke, Mark A, Eshleman, Susan H, Kofron, Ryan, Adeyeye, Adeola, Burns, David, Rinehart, Alex R, Margolis, David, Cohen, Myron S, McCauley, Marybeth, Hendrix, Craig W · 2020 · The Lancet HIV

Abstract

Background Long-acting injectable cabotegravir (CAB LA) is a novel integrase inhibitor in advanced clinical development for HIV treatment and HIV prevention. We investigated the terminal pharmacokinetics and safety of CAB LA after final injection as part of a Phase 2 study. Methods We performed a randomized, double-blind placebo-controlled trial at 8 sites in the United States (US), sub-Saharan Africa, and Brazil. Participants, age 18–65, HIV-uninfected and at low-risk for HIV, were randomized 3:1 to CAB LA or placebo. Participants received CAB LA at one of two doses/intervals (800 mg as a split 2 × 2mL injection or 600 mg as a single 3mL injection), which were aggregated for this analysis. The current analysis includes participants who received at least one injection and examines the tail phase (time from final injection to 52–76 weeks post-final injection). The outcomes were safety and pharmacokinetics. Safety was reported as incidence rates of grade 2 or higher adverse events. The apparent terminal phase half-life (t1/2app) and time to decay of CAB drug concentration to below the lower limit of quantification (LLOQ) were estimated using non-compartmental methods. The trial was registered with ClinicalTrials.gov, number NCT02178800. This trial is completed. Findings Overall, 177 (133 CAB, 44 PBO) participants received at least one injection. Median age was 31 years, 117 (66·1%) were female, 123 (69·5%) were non-white, 93 (52·5%) were from the US. Rates of grade 2 or higher adverse events on CAB were higher in the injection phase compared to the tail phase. At one time point from 52–60 weeks and at 76 weeks after final injection, 9 (22·5%) and 4 (13·3%) of males, respectively, had detectable CAB concentrations; 52 (63·4%) and 27 (42·2%) of females had detectable CAB concentrations at those time points. The estimated median time from last injection to CAB concentration below the LLOQ was 43·7 (range 20·4–152·5) weeks for males and 67·3 (range 17·7–225·5) weeks for females. Terminal phase half-life was 32% longer for female sex at birth participants compared to male participants, and 33% longer for participants with body mass index (BMI) above vs. below the study median of 27·2 for females and 25·0 for males. Interpretation The clinical importance of the long pharmacokinetic tail, significantly longer for females compared to males, and those with higher BMI, will need to be addressed in pivotal trials of treatment and prevention. Trial Registration: ClinicalTrials NCT02178800

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3018(20)30106-5

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 183

Metadata

Authors
Landovitz, R. J., Li, S., Eron, J. J., Grinsztejn, B., Dawood, H., Liu, A. Y., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M. A., Eshleman, S. H., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A. R., Margolis, D., Cohen, M. S., McCauley, M., & Hendrix, C. W.
Venue
The Lancet HIV
Publisher
Elsevier BV
Published
2020-07
Volume
7
Issue
7
Pages
e472-e481
ISSN
2352-3018 (ISSN-L)
OpenAlex
W3030616052
Cited by
183
References
4
FWCI
2.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. https://app.cochat.ai/papers/10.1016/s2352-3018(20)30106-5
The paper
Landovitz, R. J., Li, S., Eron, J. J., Grinsztejn, B., Dawood, H., Liu, A. Y., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M. A., Eshleman, S. H., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A. R., Margolis, D., . . . Hendrix, C. W. (2020). Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(20)30106-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.